The combined use of PARPIs with histone deacetylase inhibitors (HDIs) can sensitize cancer cells to PARPIs because HDIs block the deacetylation of heatshock protein 90 (HSP90), which leads to the degradation of several proteins such as BRCA1, RAD52, ATR, and CHK1. Here, BRCA1 is linked to cancer.